Abstract
Breast cancer development and progression is regulated by crosstalk between steroid hormones (SHs) (e.g., estrogens, progestins and androgens) and growth factors such as insulin-like growth factors (IGFs), insulin, epidermal growth factors (EGFs), transforming growth factors, and vascular endothelial growth factor. The biological effects of SHs are mediated by the nuclear receptors acting as transcriptional activators. Steroid hormone receptors (SRs), in addition to being induced by their own ligands, are also regulated by cellular kinases activated by growth factors. Growth factors are known to influence the expression and activity of SRs as well as regulate the action of various SR transcriptional cofactors. In turn, the expression of growth factor receptors, their ligands, and signaling molecules is often controlled by SHs. This review will focus on crosstalk between the IGF-I system and several SRs implicated in breast cancer.
Keywords: C-terminal LBD, AF1 (activation function 1), cyclin D1 protein expression, Progestins, Androgens, Src homology 2
Current Pharmaceutical Design
Title: Crosstalk between IGF Signaling and Steroid Hormone Receptors in Breast Cancer
Volume: 13 Issue: 7
Author(s): Diego Sisci and Eva Surmacz
Affiliation:
Keywords: C-terminal LBD, AF1 (activation function 1), cyclin D1 protein expression, Progestins, Androgens, Src homology 2
Abstract: Breast cancer development and progression is regulated by crosstalk between steroid hormones (SHs) (e.g., estrogens, progestins and androgens) and growth factors such as insulin-like growth factors (IGFs), insulin, epidermal growth factors (EGFs), transforming growth factors, and vascular endothelial growth factor. The biological effects of SHs are mediated by the nuclear receptors acting as transcriptional activators. Steroid hormone receptors (SRs), in addition to being induced by their own ligands, are also regulated by cellular kinases activated by growth factors. Growth factors are known to influence the expression and activity of SRs as well as regulate the action of various SR transcriptional cofactors. In turn, the expression of growth factor receptors, their ligands, and signaling molecules is often controlled by SHs. This review will focus on crosstalk between the IGF-I system and several SRs implicated in breast cancer.
Export Options
About this article
Cite this article as:
Sisci Diego and Surmacz Eva, Crosstalk between IGF Signaling and Steroid Hormone Receptors in Breast Cancer, Current Pharmaceutical Design 2007; 13 (7) . https://dx.doi.org/10.2174/138161207780249182
DOI https://dx.doi.org/10.2174/138161207780249182 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blockers of Voltage-Gated Sodium Channels for the Treatment of Central Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Thermal Imaging Techniques for Breast Screening - A Survey
Current Medical Imaging Biodiversity and Chemodiversity: Future Perspectives in Bioprospecting
Current Drug Targets Diagnostic and Prognostic Value of 18F-FDG PET/CT in Male Breast Cancer: Results From a Bicentric Population
Current Radiopharmaceuticals Cardiovascular Risk in Patients with Primary Hyperparathyroidism
Current Pharmaceutical Design Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review
Current Molecular Pharmacology Biosynthetic and Metabolic Alterations in Cancer Growth
Current Angiogenesis (Discontinued) Magnetic Nanoparticles in Brain Disease Diagnosis and Targeting Drug Delivery
Current Nanoscience Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design Iridoids Analysis by Different Analytical Techniques and its Role as Pharmacologic Agents: A Review
Current Bioactive Compounds Opioid Free Anaesthesia and Cancer
Current Pharmaceutical Design Subject Index To Volume 6
Current Molecular Medicine Nuclear Retinoic Acid Receptor Beta as a Tool in Chemoprevention Trials
Current Medicinal Chemistry Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?
Anti-Cancer Agents in Medicinal Chemistry Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids
Current Drug Metabolism Mesenchymal Stem Cells Induced In Vitro Generated Regulatory-T Cells: Potential Soldiers of Transplantation Biology
Current Biotechnology Glucocorticoid Receptor Interacting Co-regulators: Putative Candidates for Future Drug Targeting Therapy
Mini-Reviews in Medicinal Chemistry Synthesis and Evaluation of Novel Erucin Analogues as Potential Antitumor Compounds
Letters in Organic Chemistry A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets